CVS Group PLC (CVSG) — Investment Research Note

Executive summary

CVS is a UK-listed corporate operator of ~475 veterinary practices in the UK and Australia, plus diagnostic laboratories and an online pet pharmacy (Animed Direct), generating £673m of FY25 revenue and ~£135m of adjusted EBITDA. The trajectory over five years has been steady mid-single-digit revenue growth (FY22 £554m → FY25 £673m) and resilient ~19–20% adjusted EBITDA margins, but with persistent dilution between adjusted and statutory profit driven by amortisation of acquired patient records and recurring contingent consideration on bolt-ons. The single most important point for valuation today is the CMA market investigation: the Provisional Decision (Oct 2025) and pending Final Decision (Spring 2026) cap pricing/transparency, while Australia expansion plus the move to the Main Market provide an offset.

Fair value estimate

• Methodology: Blend of EV/EBITDA multiple (8–10x FY26E adj EBITDA) cross-checked with forward P/E (13–16x adj EPS).
• Key assumptions: FY26 adj EBITDA £141.9m (company-compiled consensus, 2026-02 interim); net bank debt £160.2m at Dec-25 plus £102m IFRS-16 lease liabilities; ~70.2m shares post-buyback; FY26 adj EPS ~85–90p (H1 was 40.2p with full-year accretion from Australia acquisitions).
• EV/EBITDA: 8–10x × £141.9m = EV £1,135–£1,419m. Less net bank debt £160m gives equity £975–£1,259m (we treat leases as operating rather than debt-like here, given the fragmented multi-site portfolio). Per share: 1,390–1,795p.
• P/E sanity check: 14–16x × 87p = 1,220–1,390p.
• Fair value range: 1,300–1,650p per share, implied market cap £912m–£1,158m.
• Compared to £811.7m current market cap (~1,156p): absolute upside of +12% to +43%, midpoint ~+27%.

Sector context

• Confirmed sector: Health Care (Health Care Providers / Animal Healthcare services subsector). Note: economically closer to consumer professional services than to pharma or medtech.
• Quality/growth/leverage profile is in line with sector veterinary peers (IVC Evidensia – private; VetPartners – private; Mars Veterinary Health – private). On listed comparables CVS is one of very few pure plays globally; nearest listed analogues are Greencross/VetPartners (Australia, private), Pets at Home (PETS LN, with vet JV exposure), and US peers like Idexx (diagnostics, much higher quality/multiple).
• Listed peers: Pets at Home (PETS LN); Idexx Labs (IDXX US) for diagnostics adjacency; Dechra Pharmaceuticals (recently taken private) was the closest UK animal-health peer.

Investment thesis

• Australia platform building scale at attractive multiples. 33 practices / 55 sites in Australia by H1 2026 for cumulative ~£100m investment; acquisition EBITDA multiples lower than UK and IRRs comfortably above 10% hurdle, with purchasing synergies emerging. CMA-driven UK pause has redirected capital here productively 2026-02 interim.
• Cash-generative, modestly leveraged platform with optionality on UK reopening. Adj operating cash conversion 75% in H1 26, leverage 1.41x vs <2.0x guidance, committed facilities to Feb 2028. Once CMA Final Decision lands (Spring 2026), UK acquisitions can resume "at appropriate multiples" 2026-02 interim.
• Structural pet-care demand and COVID puppy ageing cohort. Membership of the Healthy Pet Club preventative scheme stable at ~516k; management cites the cohort of COVID-era pets ageing into more treatment-intensive years as a multi-year tailwind 2025-10 FY25 results.

Key risks

• CMA remedies cap pricing power. Provisional Decision (Oct 2025) requires price-list publication and ownership transparency; risk of further intervention on prescription/medicine pricing not fully scoped 2026-02 interim, 2025-10 FY25.
• UK consumer softness pressuring like-for-like. LFL only +2.7% in H1 26 vs medium-term 4–8% target; FY25 LFL was just +0.2%; UK practice footfall described as soft 2026-02 interim.
• Wage/NIC inflation erodes margins absent pricing. ~£11m annualised drag from NLW + employer NIC changes from April 2025; adj EBITDA margin slipped to 19.0% in H1 26 from 19.3% prior-year 2026-02 interim. Also: heavy gap between statutory (basic EPS 10.9p H1) and adjusted EPS (40.2p), driven by amortisation and contingent consideration — "earnings quality" theme.

Operating leverage

CVS has moderate operating leverage, not high. Cost base is dominated by clinical staff (~34% of revenue) and cost of goods/drugs (~22%), both of which scale broadly with volume; gross margin is ~44% 2026-02 interim. Fixed elements are practice property/leases, central admin (£21m in FY25, c.3% of revenue), and depreciation/amortisation. The result: every 10% incremental revenue at maintained mix would likely add ~£12–14m of EBITDA (gross profit drop-through net of variable staff additions), i.e. ~10% to current EBITDA — not a multi-bagger. Greenfield sites and recently relocated practices do show stronger incremental margins, but the overall portfolio is closer to a typical services business than a software platform. Inflection points would be (i) practice utilisation lifting in mature sites without new vet hires, (ii) Australia reaching purchasing-synergy scale, and (iii) Animed Direct breaking out of subscale (H1 26 EBITDA was zero on £25.5m revenue) 2026-02 interim.

Value-trap signals

• Recurring "exceptional" and business-combination charges that consistently bridge adjusted to statutory profit — H1 26 £8.9m business combination costs + £3.5m exceptionals; FY25 £14.9m + £6.0m. These are real cash items (contingent consideration paid £4.2m H1 26), so quality of adjusted EBITDA is overstated.
• CMA regulatory overhang capping pricing — structural margin headwind, not a one-off.
• LFL deceleration (FY25 +0.2% vs ambition of 4–8%) — UK practice volumes structurally softer.
• Statutory EPS down 23% in H1 26 while adjusted EPS up 6% — divergence widening.

Earnings vs. expectations

Across the period, CVS has generally met or marginally exceeded internally-compiled consensus on adjusted EBITDA. FY25 came in at £134.6m vs internal consensus £133.3m (July 2025 update: "in line with market consensus"). H1 26 reported "in line with market expectations" and Board confidence in FY26 consensus of £141.2–142.5m reiterated. However the Group has consistently missed its own medium-term LFL ambition (4–8%): FY24 LFL 2.9%, FY25 0.2%, H1 26 2.7%. So the pattern is "meets EBITDA on cost control + Australia M&A, misses organic growth ambitions" — the cyber incident in April 2024 also caused a clear miss on H2 FY24 LFL.

Conviction

4 — high. Anchored by (i) clean, well-disclosed financials with thorough segmental reporting and APM reconciliations, (ii) a stable, predictable business model with multi-year track record, (iii) two independent valuation methodologies (EV/EBITDA and P/E) converging on a similar range. Limited by (i) CMA Final Decision still pending and could shift sentiment materially in either direction, and (ii) the persistent adjusted-vs-statutory gap makes "true" earnings power debatable.

Driver scoring rationale (summary)

• AI beneficiary (10): Veterinary services has no meaningful AI receiver exposure. CVS is spending on AI (consultation note tooling, scheduling) but captures none of the value-chain economics; mentions in filings do not translate to revenue. Slight positive: proprietary patient data could in theory feed pharma/dx AI partners, but no evidence of monetisation.
• Operating leverage (45): Moderate; staff-heavy services model with some fixed central/depreciation costs but limited drop-through compared to software/platform models.
• Earnings surprise trend (55): Mostly in-line; meets EBITDA, misses organic-growth ambitions.
• Cyclicality (30): Defensive consumer health services; some discretionary exposure but recurring HPC membership smooths it.
• Moat (45): Local switching costs and regulatory licensing, but actively eroding under CMA scrutiny and online pharmacy competition.
• Leverage (40): 1.41x net debt/EBITDA; well within covenants; plus ~£102m IFRS-16 leases.
• Earnings quality (45): Cash conversion ~75% is solid, but recurring contingent consideration and amortisation create a persistent 50%+ wedge between statutory and adjusted EPS.
• Management quality (60): Decent execution: divested loss-making Netherlands/Ireland (2024), sold Crematoria at 10x EBITDA (2025), opportunistic Australia entry. Some red flags on remuneration vote (~22% against in 2025 AGM).
• Growth momentum (50): Revenue mid-single digit; LFL decelerated to low-single-digit; Australia provides inorganic top-up.

Overall score (230/1000)

Poor fit for this investor: no AI receiver angle, moderate (not high) operating leverage, valuation is fair-to-slightly-cheap but not so cheap that it overcomes the absence of the primary thesis pillars. Quality acceptable, downside protection adequate. Not a focus for an AI-themed strategy.